Marker Therapeutics Shares Are Trading Lower. The Company Reported Results From Its Phase 1 APOLLO Study of MT-601 in Relapsed Lymphoma.
Marker Therapeutics Shares Are Trading Lower. The Company Reported Results From Its Phase 1 APOLLO Study of MT-601 in Relapsed Lymphoma.
Marker Therapeutics的股票正在下跌。該公司報告了其針對複發性淋巴瘤的1期APOLLO研究中Mt-601的結果。
Marker Therapeutics Shares Are Trading Lower. The Company Reported Results From Its Phase 1 APOLLO Study of MT-601 in Relapsed Lymphoma.
Marker Therapeutics的股票正在下跌。該公司報告了其針對複發性淋巴瘤的1期APOLLO研究中Mt-601的結果。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間